| 000 | 01431 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250512005410.0 | ||
| 264 | 0 | _c19900129 | |
| 008 | 199001s 0 0 eng d | ||
| 022 | _a0344-5704 | ||
| 024 | 7 |
_a10.1007/BF00692355 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLind, M J | |
| 245 | 0 | 0 |
_aProlongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. _h[electronic resource] |
| 260 |
_bCancer chemotherapy and pharmacology _c1989 |
||
| 300 |
_a139-42 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xblood |
| 650 | 0 | 4 | _aChromatography, High Pressure Liquid |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIfosfamide _xadministration & dosage |
| 650 | 0 | 4 |
_aLung Neoplasms _xblood |
| 650 | 0 | 4 |
_aMesna _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aObesity _xmetabolism |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aTissue Distribution _xdrug effects |
| 700 | 1 | _aMargison, J M | |
| 700 | 1 | _aCerny, T | |
| 700 | 1 | _aThatcher, N | |
| 700 | 1 | _aWilkinson, P M | |
| 773 | 0 |
_tCancer chemotherapy and pharmacology _gvol. 25 _gno. 2 _gp. 139-42 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/BF00692355 _zAvailable from publisher's website |
| 999 |
_c2563124 _d2563124 |
||